SAN DIEGO, Feb. 19, 2016 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or the “Company”) will announce its fourth quarter and full year 2015 financial results after market close on Tuesday, March 8, 2016.
TearLab’s Chief Executive Officer, Seph Jensen and Chief Financial Officer, Wes Brazell, will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Fourth Quarter and Full Year 2015 Results Conference Call Details:
Date: Tuesday, March 8, 2016
Time: 4:30 p.m. ET
Live Call: 877-303-1593
Replay: 855-859-2056 (Pass Code: 54603879)
The call will also be broadcast live and archived on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investor's section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity® Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning our future financial performance, the future success and performance of our principal product and the future status of reimbursement for our technology. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed with the SEC on November 6, 2015. We do not undertake to update any forward-looking statements.
CONTACTS: Investors: Stephen Kilmer (647) 872-4849 [email protected]


BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



